Cantor Fitzgerald Weighs in on Legend Biotech FY2026 Earnings

Legend Biotech Co. (NASDAQ:LEGN - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Legend Biotech in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Bienkowski forecasts that the company will post earnings of $0.24 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $55.00 price target on the stock. The consensus estimate for Legend Biotech's current full-year earnings is ($1.31) per share.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.33. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. The business had revenue of $195.05 million during the quarter, compared to analysts' expectations of $190.83 million. During the same period in the previous year, the business earned ($0.16) earnings per share. The business's revenue was up 107.8% compared to the same quarter last year.

Several other equities research analysts have also recently issued reports on LEGN. HC Wainwright reiterated a "buy" rating and issued a $75.00 price objective on shares of Legend Biotech in a report on Wednesday, April 16th. Truist Financial lowered their price target on Legend Biotech from $88.00 to $71.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Royal Bank of Canada reissued an "outperform" rating and issued a $84.00 price objective on shares of Legend Biotech in a research note on Tuesday, April 22nd. Guggenheim restated a "neutral" rating on shares of Legend Biotech in a report on Wednesday, March 12th. Finally, Morgan Stanley dropped their target price on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating for the company in a report on Monday, March 17th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $76.20.

Legend Biotech Price Performance

NASDAQ LEGN traded up $2.86 on Tuesday, hitting $37.64. The company had a trading volume of 2,855,319 shares, compared to its average volume of 1,318,094. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90. The company's fifty day moving average price is $31.50 and its 200-day moving average price is $34.53. The company has a market capitalization of $6.92 billion, a PE ratio of -39.62 and a beta of 0.13. Legend Biotech has a 12-month low of $27.34 and a 12-month high of $60.87.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in LEGN. Asset Management One Co. Ltd. increased its stake in Legend Biotech by 26.1% in the fourth quarter. Asset Management One Co. Ltd. now owns 11,085 shares of the company's stock valued at $360,000 after purchasing an additional 2,297 shares during the last quarter. Rhumbline Advisers grew its holdings in Legend Biotech by 5.9% in the 4th quarter. Rhumbline Advisers now owns 27,638 shares of the company's stock valued at $899,000 after buying an additional 1,544 shares during the period. Empire Life Investments Inc. grew its holdings in Legend Biotech by 38.5% in the 4th quarter. Empire Life Investments Inc. now owns 136,731 shares of the company's stock valued at $4,449,000 after buying an additional 38,043 shares during the period. New York State Common Retirement Fund increased its stake in shares of Legend Biotech by 196.1% during the 4th quarter. New York State Common Retirement Fund now owns 59,276 shares of the company's stock valued at $1,929,000 after acquiring an additional 39,256 shares during the last quarter. Finally, Alberta Investment Management Corp lifted its holdings in shares of Legend Biotech by 143.3% during the 4th quarter. Alberta Investment Management Corp now owns 135,259 shares of the company's stock worth $4,401,000 after acquiring an additional 79,663 shares during the period. Hedge funds and other institutional investors own 70.89% of the company's stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).